Literature DB >> 8163342

Adenovirus vector-mediated in vivo gene transfer into adult murine retina.

J Bennett1, J Wilson, D Sun, B Forbes, A Maguire.   

Abstract

PURPOSE: To determine whether a reporter gene can be introduced into the adult mammalian retina in vivo through means of a recombinant replication-deficient adenovirus.
METHODS: A dilution series of purified Ad.CMVlacZ ranging from 10(5) to 10(11) pfu/ml was prepared and microinjected into the subretinal space of adult CD-1 mice. This virus contained the cytomegalovirus (CMV)-promoted Escherichia coli reporter gene, lacZ. LacZ expression was assessed in enucleated eyes from 0 to 95 days after injection by beta-galactosidase (beta-Gal) assay.
RESULTS: The efficiency of transfection increased as a function of concentration of recombinant virus injected. Eyes injected with greater than 10(7) pfu of Ad.CMVlacZ demonstrated beta-Gal activity lasting at least 95 days. LacZ expression was apparent only in those cells directly exposed to the adenovirus. LacZ expression was observed in the retinal pigment epithelium (RPE) at high efficiency at 48 hours after exposure. By 2 weeks after injection of > 10(7) pfu, lacZ was also expressed in photoreceptors, but at lower density.
CONCLUSIONS: These results demonstrate that high efficiency stable transfer of functional genes can be achieved in vivo in post-mitotic mammalian retina using recombinant adenoviral vectors. Adenovirus vectors appear to be a promising means for delivering therapeutic genes in vivo to the mammalian neural retina and particularly to the RPE.

Entities:  

Mesh:

Year:  1994        PMID: 8163342

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  45 in total

Review 1.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

Review 2.  What Is Next for Retinal Gene Therapy?

Authors:  Luk H Vandenberghe
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-15       Impact factor: 6.915

3.  Adenovirus-mediated delivery of catalase to retinal pigment epithelial cells protects neighboring photoreceptors from photo-oxidative stress.

Authors:  T S Rex; I Tsui; P Hahn; A M Maguire; D Duan; J Bennett; J L Dunaief
Journal:  Hum Gene Ther       Date:  2004-10       Impact factor: 5.695

Review 4.  Regulatable gene expression systems for gene therapy applications: progress and future challenges.

Authors:  S Goverdhana; M Puntel; W Xiong; J M Zirger; C Barcia; J F Curtin; E B Soffer; S Mondkar; G D King; J Hu; S A Sciascia; M Candolfi; D S Greengold; P R Lowenstein; M G Castro
Journal:  Mol Ther       Date:  2005-08       Impact factor: 11.454

5.  Lentiviral mediated gene delivery to the anterior chamber of rodent eyes.

Authors:  Pratap Challa; Coralia Luna; Paloma B Liton; Beth Chamblin; John Wakefield; Ram Ramabhadran; David L Epstein; Pedro Gonzalez
Journal:  Mol Vis       Date:  2005-06-21       Impact factor: 2.367

Review 6.  Regulatable gene expression systems for gene therapy.

Authors:  Nuria Vilaboa; Richard Voellmy
Journal:  Curr Gene Ther       Date:  2006-08       Impact factor: 4.391

Review 7.  Non-replicating expression vectors: applications in vaccine development and gene therapy.

Authors:  K J Limbach; E Paoletti
Journal:  Epidemiol Infect       Date:  1996-06       Impact factor: 2.451

Review 8.  Gene therapy for inherited retinal degeneration.

Authors:  R R Ali; M B Reichel; D M Hunt; S S Bhattacharya
Journal:  Br J Ophthalmol       Date:  1997-09       Impact factor: 4.638

9.  Phenotype correction in retinal pigment epithelium in murine mucopolysaccharidosis VII by adenovirus-mediated gene transfer.

Authors:  T Li; B L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

Review 10.  Promising and delivering gene therapies for vision loss.

Authors:  Livia S Carvalho; Luk H Vandenberghe
Journal:  Vision Res       Date:  2014-08-02       Impact factor: 1.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.